Heron Therapeutics’ High-Wire Act: Can a Fast-Growing Acute Care Franchise Outrun Its Balance Sheet Risk?
In early 2026, Heron Therapeutics is running two races at once: accelerating adoption of its hospital-focused Acute Care drugs while its legacy oncology busines…